Athira Pharma, Inc. (NASDAQ:LONA) Given Average Rating of “Hold” by Brokerages

Athira Pharma, Inc. (NASDAQ:LONA) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.00.

LONA has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research report on Monday, May 11th. Piper Sandler began coverage on Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Wall Street Zen upgraded Athira Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Institutional Trading of Athira Pharma

Institutional investors and hedge funds have recently modified their holdings of the business. Focus Partners Wealth acquired a new position in shares of Athira Pharma in the 3rd quarter valued at about $35,000. Renaissance Technologies LLC raised its stake in Athira Pharma by 44.7% during the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after acquiring an additional 23,223 shares during the period. Jane Street Group LLC acquired a new stake in Athira Pharma during the fourth quarter worth about $100,000. Spruce Street Capital LP acquired a new stake in Athira Pharma during the fourth quarter worth about $2,980,000. Finally, ADAR1 Capital Management LLC bought a new position in Athira Pharma in the fourth quarter worth about $2,891,000. 57.12% of the stock is owned by institutional investors and hedge funds.

Athira Pharma Stock Down 10.4%

NASDAQ:LONA opened at $8.53 on Thursday. The firm has a market capitalization of $80.13 million, a P/E ratio of -1.64 and a beta of 2.01. Athira Pharma has a one year low of $3.24 and a one year high of $14.21. The stock has a 50-day moving average price of $9.14.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.73) earnings per share for the quarter. As a group, analysts expect that Athira Pharma will post -3.12 earnings per share for the current fiscal year.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.